Latigo Biotherapeutics: Blue Owl reports 5.43% stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Latigo Biotherapeutics, Inc. (LTGO) was named in a Schedule 13G in which Blue Owl Capital Holdings LP reported beneficial ownership of 3,596,780 common shares, equal to 5.43% of the class. Blue Owl reported sole voting and dispositive power over all 3,596,780 shares and zero shared power in either category. The percentage calculation uses 66,299,347 Latigo common shares outstanding as of November 2, 2026.
Key Figures
Key Terms
beneficial ownership regulatory
sole voting power regulatory
sole dispositive power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.